Breast Cancer Connect
  • Saved

5yr

The OncoMasTR test predicts distant recurrence in estrogen receptor-positive, HER2-negative early-stage breast cancer: A validation study in ABCSG Trial 8 - PubMed

The OncoMasTR test predicts distant recurrence in estrogen receptor-positive, HER2-negative early-stage breast cancer: A validation study in ABCSG Trial 8 - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34380638/

OncoMasTR Risk Score is highly prognostic for DR in postmenopausal women with ER-positive, HER2-negative primary breast cancer with 0-3 involved lymph nodes. In combination with prior validation studies, this fully...

  • Saved

5yr

MONARCH 2: subgroup analysis of patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2- advanced breast cancer - PubMed

MONARCH 2: subgroup analysis of patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2- advanced breast cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34376533/

doi: 10.1158/1078-0432.CCR-20-4685. Online ahead of print. 1 Department of Gynaecology and Obstetrics, UZ Leuven. 2 Breast Unit, Royal Marsden Hospital. 3 Department of Breast Surgery, Kyoto University. 4 Division of...

  • Saved

5yr

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group - PubMed

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34357781/

doi: 10.1200/JCO.21.00944. Online ahead of print. 1 The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. 2 Cancer Research at UCC, College of Medicine and Health, University College Cork,...

  • 5yr
    Key Points • Conclusion/Relevance: “The combination of exemestane and entinostat did not improve survival in AI-resistant advanced HR-positive, HER2-negative breast cancer.” • In this multicenter, randomized, double-blind, placebo-controlled phase III study (i.e., E2112) involving Show More
  • Saved

5yr

First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta - PubMed

First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34207443/

In this analysis, we describe population-based outcomes for first-line treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) combined with an aromatase inhibitor (AI). All patients who were prescribed CDK4/6i +...

  • 5yr
    Key Points • Conclusion/Relevance: “The adoption of CDK4/6i + AI as a first-line treatment for HR-positive, HER2-negative MBC in Alberta is justified based on our favourable PFS and early OS outcomes.” • In the Show More
  • Saved

5yr

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials - PubMed

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34271289/

doi: 10.1016/j.breast.2021.07.002. Online ahead of print. 1 Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, No.123 Huifu West, Yuexiu District, Guangzhou, 510080, Guangdong,...